Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04586426 · ClinicalTrials.gov registry record · Phase 1

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
228
Enrollment target
20
Study locations

NCT04586426 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 228 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04586426, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
228 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Teclistamab
  • DRUG Talquetamab

Study Locations (20)

Other

  • St Vincents Hospital Melbourne - Fitzroy
  • Royal Perth Hospital - Perth
  • Hadassah Medical Center - Jerusalem

New York

  • Mount Sinai Medical Center - New York
  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Atrium Health - Charlotte
  • Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center - Winston-Salem

Alberta

  • Arthur J E Child Comprehensive Cancer Centre - Calgary
  • Alberta Health Services - Edmonton

Alabama

  • University of Alabama at Birmingham, Comprehensive Cancer Center - Birmingham

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Colorado

  • Colorado Blood Cancer Institute - Denver

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2020-12-15
Est. Completion 2026-10-27
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04586426

The ClinicalTrials.gov registry entry for NCT04586426 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (58% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab is the first listed.

NCT04586426 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT04586426 about?

NCT04586426 is a clinical study titled "A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with ...

What is the current status of trial NCT04586426?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 228 participants. The study started on 2020-12-15. Estimated completion is 2026-10-27.

What conditions does trial NCT04586426 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT04586426?

The interventions under investigation include: Teclistamab (DRUG), Talquetamab (DRUG).

Who is sponsoring clinical trial NCT04586426?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04586426 being conducted?

This trial has 20 study locations across Alabama, Arkansas, Colorado, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.